Moreover, our data indicate that in the absence of Suv39h1, CD8+ TILs are poised to more effectively respond to TCR-activation and to become highly cytolytic upon PD-1-blockade, underlying the increased tumor rejection compared to WT mice. This evidence concerns the gene SUV39H1 and neoplasm.